Welireg significantly improved quality-adjusted survival time over Afinitor in advanced renal cell carcinoma, with a mean Q-TWiST of 17.47 months versus 14.81 months. The relative gain in Q-TWiST with ...
Imperial College London investigators compared focal therapy with prostate removal surgery for men with prostate cancer that ...
First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors Eighty-five larotrectinib patients and 28 non-TRK-inhibitor SoC patients were ...
The survival benefit observed with Padcev plus Keytruda was “unlike anything we’d seen before” for advanced bladder cancer, according to an expert. For patients with advanced bladder cancer, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results